Skip to main content
. Author manuscript; available in PMC: 2023 Dec 11.
Published in final edited form as: N Engl J Med. 2023 Mar 27;388(23):2159–2170. doi: 10.1056/NEJMoa2302312

Figure 2. Progression-free Survival in the Two Cohorts.

Figure 2.

Shown are Kaplan–Meier estimates of progression-free survival in the population of patients with advanced or recurrent endometrial cancer with mismatch repair–deficient (dMMR) disease (Panel A) or mismatch repair–proficient (pMMR) disease (Panel B). Tick marks in both panels indicate censoring of data. Patients in both the pembrolizumab and the placebo groups received combination chemotherapy with paclitaxel and carboplatin. NR denotes not reached.